For its fourth quarter of 2024, CRISPR booked revenue of just under $36 million. That was well under the more than $201 million the company earned in the same period of 2023. On the bottom line, ...

Facial recognition shows us that when complex and evolving technology such as AI is deployed in the real world, as opposed to ...

TD Cowen has upgraded CRISPR Therapeutics (NASDAQ:CRSP) to hold from sell, stating it now sees less downside to the stock. "We believe Casgevy expectations have bottomed out in the near term and ...

Ongoing launch of CASGEVY® continues to gain momentum; new cell patient collection initiations expected to significantly ...

ZUG, Switzerland and BOSTON - CRISPR Therapeutics (NASDAQ:CRSP) reported a narrower-than-expected loss and revenue that surpassed analyst estimates for the fourth quarter of 2024, sending shares up 0.

Scientists in the polo-obsessed nation have produced world's first genetically edited horses, designed to outrun champion ...

The Trump administration recently announced the National Institutes of Health will make big changes in the way it funds ...

Ongoing launch of CASGEVY ® continues to gain momentum; new cell patient collection initiations expected to significantly grow in 2025- -More than 50 authorized treatment centers (ATCs) activated ...

Shares of the satellite services company ViaSat took a dive Tuesday. Shares lost 21% closing at $8.83, while the was flat and the gained about 0.3%. Globalstar stock added 4%, while shares of AST ...

A research team has made a major discovery on how the CUL5 gene affects CAR-T cell therapy, an advanced cancer therapy. The study reveals that reducing the activity of the CUL5 gene helps CAR-T cells ...

The chip maker is likely to be watching OpenAI after a consortium headed by Elon Musk offered almost $100 billion for the ...

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the fourth quarter and full year ended December 31, 2024, and provided ...